Wednesday was one of the rare good days for the beleaguered marijuana industry, with stocks in the sector experiencing significant lifts. One weedie that saw quite the price gain on the day was multistate operator Curaleaf Holdings (CURLF 19.72%), which booked a nearly 20% increase. That compared most favorably to the sleepy S&P 500 index's less than 0.2% improvement.
To a great degree, the future success of Curaleaf and its peers depends on the development of marijuana legalization in this country. At the moment, federal officials are contemplating a proposed rescheduling of the drug, from its most hazardous Schedule I category to the far milder grouping of Schedule III. This would, for all intents and purposes, make the drug legal nationwide.
That potential change seemed to gain significant momentum on Wednesday during a confirmation hearing before the U.S. Senate's Judiciary Committee. President Donald Trump's nominee to lead the Drug Enforcement Administration (DEA), Terrance Cole, stated that reviewing the proposal will be one of his top priorities upon arrival at the DEA, if confirmed by the legislative body.
Although marijuana advocates and cannabis company investors were excited when the proposal was first formally introduced, many have been frustrated by its slow progress up the legal ladder. Cole's remarks indicate that, at the very least, he'll prioritize the matter.
Marijuana company shareholders (and those now contemplating an investment in the sector) should be careful here, though.
Even though Senators from the committee pressed Cole on how he might approach rescheduling, he declined to commit to approving it. He told them that he needs "to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。